Incannex Healthcare Inc ADR (IXHL) Stock Price, Quote & News

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety diso...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 61 4 0984 0786

Website: www.incannex.com

Address:

8 Century Circuit, Suite 105 Norwest, Sydney, Australia

JJBurch Dec. 5 at 11:17 AM

$IXHL $PMCB $QCLS $BCTX I repeat…

0 · Reply

Rasputi Dec. 5 at 11:16 AM

$IXHL imagine a press release this morning announcing the cancellation of the remaining ATM offering….. Joel please 🙏

0 · Reply

Clutch_shot Dec. 5 at 11:06 AM

$IXHL fr fr

0 · Reply

TheRhino44 Dec. 5 at 11:04 AM

$IXHL today's going to be like magic ...

0 · Reply

meanrebel Dec. 5 at 11:02 AM

$IXHL

0 · Reply

SonicPrice Dec. 5 at 10:59 AM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $S $AKAN $BULL $IXHL Holding

0 · Reply

IfeelLiketruman Dec. 5 at 10:59 AM

$IXHL back in this with starter, actually wouldn't mind a little pullback to load a little more. And being a Friday, no one should worry about it if it does...if it breaks .50 and goes instead, then I'll be happy adding up there too, win win

0 · Reply

Mapagotrades Dec. 5 at 10:45 AM

$IXHL Stock recently broke out of its channel with strong volume. This stock is very crowded has resistance at $0.50 also psychological lvl, With heavy volume / continued momentum this one can push into that $0.65 range. Stock is showing significant momentum recent bullish news: Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

0 · Reply

s3mi Dec. 5 at 10:38 AM

$IXHL

0 · Reply

Spiderjenkins Dec. 5 at 10:36 AM

$IXHL lol what a bear loser

0 · Reply

Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

Nov 20, 2025, 9:34 AM EST - 14 days ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus

Oct 22, 2025, 8:00 AM EDT - 6 weeks ago

Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Aug 26, 2025, 8:00 AM EDT - 3 months ago

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

Aug 22, 2025, 8:00 AM EDT - 3 months ago

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

Aug 19, 2025, 4:29 PM EDT - 3 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

Aug 8, 2025, 8:00 AM EDT - 4 months ago

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

Jul 31, 2025, 8:00 AM EDT - 4 months ago

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

Jul 30, 2025, 10:10 AM EDT - 4 months ago

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

Jul 30, 2025, 8:00 AM EDT - 4 months ago

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Jul 25, 2025, 7:30 AM EDT - 4 months ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Jun 24, 2025, 7:30 AM EDT - 5 months ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Jun 18, 2025, 7:30 AM EDT - 6 months ago

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Jun 17, 2025, 7:30 AM EDT - 6 months ago

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Jun 12, 2025, 7:30 AM EDT - 6 months ago

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jun 3, 2025, 7:30 AM EDT - 6 months ago

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

May 29, 2025, 7:30 AM EDT - 6 months ago

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

May 28, 2025, 4:21 PM EDT - 6 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

May 28, 2025, 7:00 AM EDT - 6 months ago

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

May 20, 2025, 7:30 AM EDT - 7 months ago

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

May 16, 2025, 9:00 AM EDT - 7 months ago

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

May 15, 2025, 8:00 AM EDT - 7 months ago

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:14 PM EDT - 7 months ago

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

May 14, 2025, 8:00 AM EDT - 7 months ago

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Apr 3, 2025, 7:30 AM EDT - 8 months ago

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Mar 7, 2025, 2:10 PM EST - 9 months ago

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Feb 18, 2025, 5:51 PM EST - 10 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Feb 14, 2025, 7:30 AM EST - 10 months ago

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Feb 4, 2025, 9:15 AM EST - 10 months ago

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Jan 23, 2025, 7:30 AM EST - 11 months ago

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Dec 2, 2024, 4:48 PM EST - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Nov 14, 2024, 4:05 PM EST - 1 year ago

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Oct 2, 2024, 4:50 PM EDT - 1 year ago

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Sep 30, 2024, 4:01 PM EDT - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

Aug 5, 2024, 7:30 AM EDT - 1 year ago

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

May 30, 2024, 7:30 AM EDT - 1 year ago

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 7, 2024, 7:30 AM EDT - 1 year ago

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

May 1, 2024, 2:33 PM EDT - 1 year ago

Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)

Feb 16, 2024, 7:30 AM EST - 1 year ago

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

Feb 1, 2024, 7:30 AM EST - 2 years ago

Clarion Clinics Open for Psychedelic-Assisted Treatments

Jan 24, 2024, 4:05 PM EST - 2 years ago

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Jan 18, 2024, 8:22 AM EST - 2 years ago

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Jan 17, 2024, 7:30 AM EST - 2 years ago

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Dec 21, 2023, 4:05 PM EST - 2 years ago

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Dec 6, 2023, 7:30 AM EST - 2 years ago

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Dec 2, 2023, 6:41 AM EST - 2 years ago

These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?

GYRE KRRO

JJBurch Dec. 5 at 11:17 AM

$IXHL $PMCB $QCLS $BCTX I repeat…

0 · Reply

Rasputi Dec. 5 at 11:16 AM

$IXHL imagine a press release this morning announcing the cancellation of the remaining ATM offering….. Joel please 🙏

0 · Reply

Clutch_shot Dec. 5 at 11:06 AM

$IXHL fr fr

0 · Reply

TheRhino44 Dec. 5 at 11:04 AM

$IXHL today's going to be like magic ...

0 · Reply

meanrebel Dec. 5 at 11:02 AM

$IXHL

0 · Reply

SonicPrice Dec. 5 at 10:59 AM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $S $AKAN $BULL $IXHL Holding

0 · Reply

IfeelLiketruman Dec. 5 at 10:59 AM

0 · Reply

Mapagotrades Dec. 5 at 10:45 AM

0 · Reply

s3mi Dec. 5 at 10:38 AM

$IXHL

0 · Reply

Spiderjenkins Dec. 5 at 10:36 AM

$IXHL lol what a bear loser

0 · Reply

Peppe1986 Dec. 5 at 10:30 AM

$IXHL Dubai they willl announce the RS … JOEL POSSS !!!!

0 · Reply

RM_Tradez Dec. 5 at 10:21 AM

$IXHL back to low volume. If we hold today on this pitiful volume I think we are good for next week. There’s only 8 trading days between now and Dubai meeting, not counting today. we all know it’s going to drop the day of. That’s not even a question. the mystery is how high can it get beforehand? I think today will tell a lot. Not expecting any pr before then either

0 · Reply

Fishbait_now Dec. 5 at 10:07 AM

$IXHL Crazy day yesterday, couldn't get over .50 - impressive show there whoever is orchestrating it, we will get to $1 in due time.

1 · Reply

Peppe1986 Dec. 5 at 10:07 AM

$IXHL GARBAGE 🗑️

0 · Reply

Buyitsellit2025 Dec. 5 at 10:00 AM

$IXHL patience slow & steady , sleep and health will win the race

0 · Reply

Peppe1986 Dec. 5 at 9:52 AM

$IXHL NO VOLUME , NO NEWS , NO MONEY … this is a SCAM … JOELLLLL POSSS !!!!!

1 · Reply

4est_fcp851 Dec. 5 at 9:50 AM

$IXHL no news. Just take your green every day

0 · Reply

Michael2737 Dec. 5 at 9:50 AM

$IXHL

0 · Reply

Fadility Dec. 5 at 9:46 AM

$IXHL if we get huge bullish volume pre market , then it means we will have news today IMO.

0 · Reply

Ond_Stock_Mind Dec. 5 at 9:43 AM

$IXHL What's going on here people? Bombard with comments!!! Increase the volume of messages here to 100 percent!!! When the shorts see you sleeping they wake up!!!

0 · Reply

Peppe1986 Dec. 5 at 9:37 AM

$IXHL GARBAGE 🗑️🗑️🗑️!!! JOELLLL POOOOSSSS !!!!!

0 · Reply

Ond_Stock_Mind Dec. 5 at 9:19 AM

$IXHL

0 · Reply

Market Cap	154.73M
Revenue (ttm)	90,000.00
Net Income (ttm)	-46.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52,100.00%
Debt to Equity Ratio	0.00

Volume	64,122,102
Avg Vol	27,788,686
Day's Range	N/A - N/A
Shares Out	346.23M
Stochastic %K	91%
Beta	7.46
Analysts	Hold
Price Target	N/A